Ligand Pharmaceuticals (LGND) Other Non-Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Other Non-Current Liabilities data on file, last reported at $17.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 20.12% year-over-year to $17.1 million; the trailing twelve-month figure through Mar 2026 stood at $17.1 million (up 20.12% YoY), and the FY2025 full-year result was $16.6 million, down 44.87% from the prior year.
• Other Non-Current Liabilities improved to $17.1 million in Q1 2026, from $16.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $43.7 million in Q3 2023 to a low of $14.2 million in Q1 2025.
• A 5-year average of $24.4 million and a median of $21.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 98.96% in 2023 and plunged 51.04% in 2025, its largest moves.
• Tracing LGND's Other Non-Current Liabilities over 5 years: stood at $27.8 million in 2022, then changed by 0.0% to $27.8 million in 2023, then grew by 8.66% to $30.2 million in 2024, then plunged by 44.87% to $16.6 million in 2025, then climbed by 2.92% to $17.1 million in 2026.
• Business Quant data shows LGND's Other Non-Current Liabilities at $17.1 million in Q1 2026, $16.6 million in Q4 2025, and $19.9 million in Q3 2025.